<DOC>
	<DOCNO>NCT00944008</DOCNO>
	<brief_summary>The primary objective : - To determine efficacy safety DepoCyte® , intrathecal ( IT ) prophylaxis neuromeningeal relapse patient 16 30 year old diagnose acute lymphoblastic leukemia standard risk treat PETHEMA LAL-RI-08 Protocol Chemotherapy schedule . The secondary objective : - To evaluate tolerability IT DepoCyte® CNS prophylaxis CNS via IT patient 16 30 year old ALL standard risk . - To compare frequency relapse CNS patient 16 30 year old standard risk ALL treat PETHEMA LAL-RI-08 Protocol Chemotherapy schedule receive DepoCyte® IT CNS prophylaxis , observe historic group patient identical risk treat PETHEMA LAL-RI/96 protocol ( systemic chemotherapy double administration triple intrathecal chemotherapy ) - To evaluate frequency systemic relapse standard risk ALL patient 16 30 year old treat PETHEMA LAL-RI-08 Protocol receive DepoCyte® IT prophylaxis CNS involvement compare observe identical risk patient treat PETHEMA LAL-RI/96 protocol ( systemic chemotherapy double administration triple IT chemotherapy )</brief_summary>
	<brief_title>PROCEDYTE : Depocyte® Administration ( Liposomal Cytarabine ) Prophylaxis Neuromeningeal Infiltration Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>A total 85 patient 16 30 year old ALL standard risk include study . The aim study determine efficacy safety administration DepoCyte® IT prophylaxis neuromeningeal relapse patient 16 30 year old diagnose ALL standard risk . The study divide : Screening : 2 week treatment Treatment : 2 year systemic treatment accord PETHEMA LAL-RI-08 Protocol ( Induction , Consolidation 1 2 , Maintenance-1 reinductions maintenance 2 reinductions ) . Patients receive DepoCyte® Induction , Consolidation 1 2 Maintenance 1 ( first year ) . Patients receive DepoCyte® Maintenance-2 ( second year ) . Follow-up : Patients study follow one year</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>According investigator opinion , patient must able carry clinical trial requirement Patient Legal Representative must volunteer sign inform consent study specific test , part common patient attention , perform . Age 16 30 Patient diagnose standard risk ALL previously treat . Standard risk ALL define follow criterion : Leukocyte count &lt; 25x109/L Absence poor prognosis cytogenetic abnormality : ( 9 ; 22 ) demonstration BCRABL rearrangement . 11q23 alteration demonstration ALL1AF4 rearrangement . Childbearing woman must negative pregnancy test must accept use effective contraception method . CNS involvement diagnosis , define presence blast centrifugate sample craneospinal fluid cellular count 5 cels/L , absence traumatic puncture ( 10 red blood cels/ml ) , neurological symptom suggest neuromeningeal involvement image test compatible , absence blast craneospinal fluid . B mature cell phenotype ( sIg+ ) Burkitt ALL cytogenetic abnormality ( [ 8 ; 14 ] , [ 2 ; 8 ] , [ 8 ; 22 ] ) ALL ( 9 ; 22 ) BCRABL rearrangement . Acute biphenotypic bilineal leukemias Acute undifferentiated leukemia History coronary valvular disease hypertensive cardiopathy Chronic hepatopathy Chronic respiratory insufficiency Chronic renal insufficiency due ALL Serious neurological disorder due ALL Abnormal ECOG ( WHO scale grade 3 4 ) do ALL Pregnant currently breast feed woman Patients participate clinical trial receive investigational agent within 30 day previous study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Depocyte®</keyword>
	<keyword>Neuromeningeal relapse</keyword>
	<keyword>Between 16 30 year old</keyword>
	<keyword>Standard risk</keyword>
</DOC>